Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.

Talitha I Verhoef; William K Redekop; Rianne Mf van Schie; Samira Bayat; Ann K Daly; Mary Geitona; Elisabeth Haschke-Becher; Dyfrig A Hughes; Farhad Kamali; Lars-Åke Levin; Vangelis G Manolopoulos; Munir Pirmohamed; Uwe Siebert; Julia C Stingl; Mia Wadelius; Anthonius de Boer; Anke-Hilse Maitland-van der Zee

doi:10.2217/pgs.12.124

Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.

Talitha I Verhoef, William K Redekop, Rianne Mf van Schie, Samira Bayat, Ann K Daly, Mary Geitona, Elisabeth Haschke-Becher (Co-Autor/-in), Dyfrig A Hughes, Farhad Kamali, Lars-Åke Levin, Vangelis G Manolopoulos, Munir Pirmohamed, Uwe Siebert, Julia C Stingl, Mia Wadelius, Anthonius de Boer, Anke-Hilse Maitland-van der Zee

Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Begutachtung

13 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	1405-1417
Fachzeitschrift	PHARMACOGENOMICS
Jahrgang	13
Ausgabenummer	12
DOIs	https://doi.org/10.2217/pgs.12.124
Publikationsstatus	Veröffentlicht - 2012

Zugriff auf Dokument

10.2217/pgs.12.124

Dieses zitieren

Verhoef, T. I., Redekop, W. K., van Schie, R. M., Bayat, S., Daly, A. K., Geitona, M., Haschke-Becher, E., Hughes, D. A., Kamali, F., Levin, L.-Å., Manolopoulos, V. G., Pirmohamed, M., Siebert, U., Stingl, J. C., Wadelius, M., de Boer, A., & Maitland-van der Zee, A.-H. (2012). Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. PHARMACOGENOMICS, 13(12), 1405-1417. https://doi.org/10.2217/pgs.12.124

@article{92255cc4a57a4edc9e2b799f0b2678cc,

title = "Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.",

keywords = "NONVALVULAR ATRIAL-FIBRILLATION, DEEP VENOUS THROMBOSIS, ORAL ANTICOAGULATION, SELF-MANAGEMENT, WARFARIN THERAPY, BLEEDING COMPLICATIONS, INTRACEREBRAL HEMORRHAGE, DABIGATRAN ETEXILATE, COUMARIN DERIVATIVES, ECONOMIC OUTCOMES",

author = "Verhoef, \{Talitha I\} and Redekop, \{William K\} and \{van Schie\}, \{Rianne Mf\} and Samira Bayat and Daly, \{Ann K\} and Mary Geitona and Elisabeth Haschke-Becher and Hughes, \{Dyfrig A\} and Farhad Kamali and Lars-{\AA}ke Levin and Manolopoulos, \{Vangelis G\} and Munir Pirmohamed and Uwe Siebert and Stingl, \{Julia C\} and Mia Wadelius and \{de Boer\}, Anthonius and \{Maitland-van der Zee\}, Anke-Hilse",

note = " Elisabethinen Hosp Linz, Inst Med \& Chem Lab Diagnost, Ctr Mol Diagnost \& Genet, Linz, Austria",

year = "2012",

doi = "10.2217/pgs.12.124",

language = "English",

volume = "13",

pages = "1405--1417",

journal = "PHARMACOGENOMICS",

issn = "1462-2416",

publisher = "Future Medicine ",

number = "12",

}

Verhoef, TI, Redekop, WK, van Schie, RM, Bayat, S, Daly, AK, Geitona, M, Haschke-Becher, E, Hughes, DA, Kamali, F, Levin, L-Å, Manolopoulos, VG, Pirmohamed, M, Siebert, U, Stingl, JC, Wadelius, M, de Boer, A & Maitland-van der Zee, A-H 2012, 'Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.', PHARMACOGENOMICS, Jg. 13, Nr. 12, S. 1405-1417. https://doi.org/10.2217/pgs.12.124

TY - JOUR

T1 - Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.

AU - Verhoef, Talitha I

AU - Redekop, William K

AU - van Schie, Rianne Mf

AU - Bayat, Samira

AU - Daly, Ann K

AU - Geitona, Mary

AU - Haschke-Becher, Elisabeth

AU - Hughes, Dyfrig A

AU - Kamali, Farhad

AU - Levin, Lars-Åke

AU - Manolopoulos, Vangelis G

AU - Pirmohamed, Munir

AU - Siebert, Uwe

AU - Stingl, Julia C

AU - Wadelius, Mia

AU - de Boer, Anthonius

AU - Maitland-van der Zee, Anke-Hilse

N1 - Elisabethinen Hosp Linz, Inst Med & Chem Lab Diagnost, Ctr Mol Diagnost & Genet, Linz, Austria

PY - 2012

Y1 - 2012

KW - NONVALVULAR ATRIAL-FIBRILLATION

KW - DEEP VENOUS THROMBOSIS

KW - ORAL ANTICOAGULATION

KW - SELF-MANAGEMENT

KW - WARFARIN THERAPY

KW - BLEEDING COMPLICATIONS

KW - INTRACEREBRAL HEMORRHAGE

KW - DABIGATRAN ETEXILATE

KW - COUMARIN DERIVATIVES

KW - ECONOMIC OUTCOMES

U2 - 10.2217/pgs.12.124

DO - 10.2217/pgs.12.124

M3 - Review article

C2 - 22966889

SN - 1462-2416

VL - 13

SP - 1405

EP - 1417

JO - PHARMACOGENOMICS

JF - PHARMACOGENOMICS

IS - 12

ER -